Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
07/01/2025 03:01
Jan 7 (Reuters) - Lotus Pharmaceutical 1795.TW :
* SAYS UNIT ALVOGEN (THAILAND) HAS CLOSED DEAL TO PURCHASE
TRADE
PERMITS AND TECHNOLOGY FROM SANOFI TO PRODUCE ALPHACHYMOTRYPSINE
CHOAY IN VIETNAM
* SAYS EXPECTS TO BOOK REVENUES FROM THE DEAL IN Q1 THIS
YEAR
* SAYS COMBINED SALES OF ALPHACHYMOTRYPSINE CHOAY IN
VIETNAM,
CAMBODIA HAVE HIT $22 MILLION IN 2023
Source text: ID:nMOP9zqkXB
Further company coverage: 1795.TW
(Reporting by Faith Hung)
((faith.hung@thomsonreuters.com;))
Recent news on Lotus Pharmaceutical
See all newsMedia: PTT is said to consider options for Taiwan-listed Lotus Pharma - Bloomberg News
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea